Researchers from the Clínic Barcelona Comprehensive Cancer Center—driven by Hospital Clínic Barcelona, IDIBAPS, and the University of Barcelona—toget1
Researchers from Hospital Clínic-IDIBAPS have led a study that has found a correlation between anti-tumour immunological activity and longevity in br1
Over the next three years, the chosen project, led by Roger Gomis (IRB) in consortium with Aleix Prat (Clínic-IDIBAPS), will study the factors that c1
Researchers from the Clínic-IDIBAPS have coordinated a study that analyses the efficacy of anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) combin1
One of the highlights of the Clínic-IDIBAPS participation in the European Society for Medical Oncology (ESMO) 2024 Congress was Dr. Josep M. Llovet’s1
A study promoted by SOLTI and published in Nature Communications describes the tumour biology associated with the activity of the drug patritumab der1
The DEFINITIVE project, led by IDIBAPS, will be conducted across 44 hospitals in a total of 7 European and associated countries to demonstrate that u1
In October, the association organized an activity to raise funds for breast cancer research at IDIBAPS.
El Corte Inglés steps up its cooperation with the Spanish Association Against Cancer (AECC) by allocating one million euros over the next five years1
These awards are organized by the Spanish Metastatic Breast Cancer Association to promote research in this area. The project presented by Dr. Aleix1
